---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-028854"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:37:03.726676+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pacira Q1 revenue $177M (+5% YoY); GAAP EPS $0.07, non-GAAP $0.60; FY guidance reiterated

## Summary
- Total revenue $177.4M (+5% YoY); EXPAREL $143.3M (+5%), ZILRETTA $26.8M (+15%), iovera° $6.2M (+21%).
- GAAP net income $2.9M ($0.07/diluted); non-GAAP net income $24.5M ($0.60/diluted); adjusted EBITDA $40.2M.
- Repurchased 2.2M shares for $50M at avg $22.28; $100M remains under authorization through Dec 2026.
- Completed ZILRETTA Phase 3 enrollment for shoulder OA; topline readout expected by end of 2026.
- Reiterated FY 2026 guidance: EXPAREL $600-620M, total revenue $745-770M, non-GAAP gross margin 77-79%.

## SEC filing metadata
- accession: 0001628280-26-028854
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/0001628280-26-028854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/pcrx-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-028854
- JSON: https://secwatch.observer/filing/0001628280-26-028854.json
- Plain text: https://secwatch.observer/filing/0001628280-26-028854.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $177.4 million, net income $2.9 million, or $0.07 per share (basic and diluted).
  - Period: the first quarter ended March 31, 2026
  - Revenue: $177.4 million
  - Net income: $2.9 million, or $0.07 per share (basic and diluted)
  - Result: reported results
  source text: reference in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2026 Financial Results -- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/0001628280-26-028854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.